Collegium Pharmaceutical Inc (NASDAQ:COLL) — Market Cap & Net Worth
Market Cap & Net Worth: Collegium Pharmaceutical Inc (COLL)
Collegium Pharmaceutical Inc (NASDAQ:COLL) has a market capitalization of $1.12 Billion ($1.12 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8294 globally and #2421 in its home market, demonstrating a -0.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Collegium Pharmaceutical Inc's stock price $35.39 by its total outstanding shares 31610976 (31.61 Million). See COLL capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Collegium Pharmaceutical Inc Market Cap History: 2015 to 2026
Collegium Pharmaceutical Inc's market capitalization history from 2015 to 2026. Data shows growth from $869.30 Million to $1.12 Billion (5.89% CAGR).
Index Memberships
Collegium Pharmaceutical Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.05% | #242 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #909 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.06% | #140 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.60 Trillion | 0.07% | #446 of 602 |
Weight: Collegium Pharmaceutical Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Collegium Pharmaceutical Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Collegium Pharmaceutical Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.43x
Collegium Pharmaceutical Inc's market cap is 1.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
13.09x
Collegium Pharmaceutical Inc's market cap is 13.09 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $492.18 Million | $1.71 Million | -$94.18 Million | 287.66x | N/A |
| 2017 | $583.54 Million | $28.48 Million | -$74.86 Million | 20.49x | N/A |
| 2018 | $542.76 Million | $280.41 Million | -$39.13 Million | 1.94x | N/A |
| 2019 | $650.55 Million | $296.70 Million | -$22.72 Million | 2.19x | N/A |
| 2020 | $633.17 Million | $310.02 Million | $26.75 Million | 2.04x | 23.67x |
| 2021 | $590.49 Million | $276.87 Million | $71.52 Million | 2.13x | 8.26x |
| 2022 | $733.37 Million | $463.93 Million | -$25.00 Million | 1.58x | N/A |
| 2023 | $972.99 Million | $566.77 Million | $48.16 Million | 1.72x | 20.21x |
| 2024 | $905.65 Million | $631.45 Million | $69.19 Million | 1.43x | 13.09x |
Competitor Companies of COLL by Market Capitalization
Companies near Collegium Pharmaceutical Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Collegium Pharmaceutical Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
Collegium Pharmaceutical Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Collegium Pharmaceutical Inc's market cap moved from $869.30 Million to $ 1.12 Billion, with a yearly change of 5.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.12 Billion | -23.56% |
| 2025 | $1.46 Billion | +61.61% |
| 2024 | $905.65 Million | -6.92% |
| 2023 | $972.99 Million | +32.67% |
| 2022 | $733.37 Million | +24.20% |
| 2021 | $590.49 Million | -6.74% |
| 2020 | $633.17 Million | -2.67% |
| 2019 | $650.55 Million | +19.86% |
| 2018 | $542.76 Million | -6.99% |
| 2017 | $583.54 Million | +18.56% |
| 2016 | $492.18 Million | -43.38% |
| 2015 | $869.30 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Collegium Pharmaceutical Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.12 Billion USD |
| MoneyControl | $1.12 Billion USD |
| MarketWatch | $1.12 Billion USD |
| marketcap.company | $1.12 Billion USD |
| Reuters | $1.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more